PolymarketFechadoVerificar disponibilidadeSem KYC2% de taxaDados de resolução verificadosRazoavelmente calibradoEste mercado foi resolvido: No
Resolvido: 11 de jun. de 2026, 09:52
Resolução verificada pelo provedor
A CoinRithm tem evidência do provedor para o vencedor e o horário de liquidação deste mercado.
Resultado Vencedor
No
A 7 dias
—
A 24 horas
8%
SurpresaProbabilidade implícita atual
Não 100%+0.9pt
Qualidade do mercado
22 / 100
Baixa qualidadeVolume 24h
799,3 €
Liquidez
—
Liquidez desconhecidaCompra / Venda
- / 0.4%
Dados do mercado
Atualizado há 70 dias
Desatualizado4/06/26, 19:3510/06/26, 0:00
Linha do Tempo de Probabilidade
Yes0%
No100%
100%
0%
Regras
As of market creation, the FDA's expected decision date for the specified application is June 10, 2026.
- This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Camurus's Oclaiz as a treatment for patients with acromegaly by June 24, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
